trending Market Intelligence /marketintelligence/en/news-insights/trending/FCAOBQdGX6ChqgBzbb0-Xw2 content esgSubNav
In This List

US FDA approves Relmada's application for antidepressant drug

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves Relmada's application for antidepressant drug

Relmada Therapeutics Inc. said the U.S. FDA cleared the company's investigational new drug application for d-Methadone, its novel, N-methyl-D-aspartate receptor antagonist.

D-Methadone is a rapid acting, oral agent for the treatment of depression, neuropathic pain and other potential central nervous system pathological conditions.

The company can now advance the development program for d-Methadone to a phase 2a proof-of-concept clinical study in patients with treatment-resistant depression.